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Abstract
Burning mouth syndrome (BMS) is idiopathic chronic oral pain, associated with depression, anxiety and 
pain symptoms. The BMS symptoms include a burning sensation in the tongue and/or other oral mucosa 
with no underlying medical or dental reasons. As many BMS patients suffer from psychiatric comorbidi-
ties, several psychotropic drugs are included in the management of BMS, reducing the complaint, while 
managing anxiety, depression and pain disorders.
In this review, a  search of  the published literature regarding the management of  BMS was conducted. 
We discuss the BMS etiology, clinically associated symptoms and available treatment options. The current 
evidence supports some BMS interventions, including alpha-lipoic acid (ALA), clonazepam, capsaicin, and 
low-level laser therapy (LLLT); however, there is a lack of robust scientific evidence, and large-scale clinical 
trials with long follow-up periods are needed to establish the role of  these BMS management options. 
This knowledge could raise the awareness of dentists, psychiatrists and general practitioners about these 
challenges and the available kinds of treatment to improve multidisciplinary management for better health 
outcomes.
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Introduction 
Burning mouth syndrome (BMS) is oral dysesthesia 
characterized by a  burning sensation in the tongue 
and/or other oral mucosa. It is associated with dry mouth 
and taste changes in the absence of  clinical/laboratory 
findings or underlying medical or dental reasons, and it 
can be debilitating in some patients.1–3 Burning mouth 
syndrome is a painful cranial neuropathy, similar to tri-
geminal neuralgia,4 with mostly unknown etiology. As 
described by the international classification of headache 
disorders, BMS recurs daily for more than 2 h/day over 
more than 3 months without clinically evident causative 
lesions; the pain is usually bilateral with fluctuating inten-
sity.5 The syndrome can also lead to sleep disturbances, 
especially in the elderly.6
Burning mouth syndrome is commonly associated with 
depression and anxiety.7 It has a  prevalence of  0.7–5% 
and appears to be more frequent in females,8 especially 
in post-menopausal women, where its prevalence is 
12–18%.9 Females report more paresthesia, oral mucosal 
pain, dysgeusia and xerostomia, while taste changes are 
less common in males.10
Burning mouth syndrome is common in psychiatric 
patients; there are reports that it affects up to 20% of the 
older hospitalized psychiatric patients11–13 and 10–20% 
of elderly outpatients.14 It could be associated with oral 
or systemic abnormalities, such as changes in hormone 
levels, infections, nutritional disturbances, denture-
related lesions, and pharmacological treatment.15 The 
BMS characteristics include changes in the mucosal 
blood flow.16
Burning mouth syndrome has been described as a psy-
chosomatic disorder predisposed by psychological stress 
or neuropathic pain, affecting the peripheral and central 
nervous system in the trigeminal pathways,3 the prefron-
tal cortex and the hippocampus.17 Patients with BMS 
process thermal stimulation differently, with changes in 
tactile sensory functions, including a lower threshold for 
cold detection, while warmth, heat and pain detection 
thresholds are higher.18–20
Immune and endocrine functions are also involved 
in BMS; a  lower level of  plasma adrenaline, a  low level 
of CD8(+) cells and a high CD4(+)/CD8(+) ratio represent 
a suppressed immune system.21 A significant increase in 
the genetic polymorphisms associated with interleukin-1β 
(IL-1β) has also been suggested.22
Changes in scores on psychiatric assessment scales have 
been identified. With the Temperament and Character 
Inventory(TCI), BMS patients have lower novelty-seek-
ing scores and self-directedness scores, while their harm-
avoidance scores are higher.23 A  Visual Analog Scale 
(VAS) study supported higher frequencies of depression, 
anxiety and cancer phobia in BMS patients.24 This is re-
flected in the F3 classification of BMS as a mood/affective 
disorder.25
Risk factors for developing BMS include stroke, a  low 
level of  education, depression, life events, anxiety, per-
sonality disorders, the excessive use of hexetidine mouth-
washes, and vitamin deficiency.26,27 Burning mouth syn-
drome is common in Parkinson’s disease, characterized 
by dopamine dysregulation, especially in the nigrostriatal 
dopaminergic pathway, as confirmed by positron emis-
sion tomography (PET).28,29
Material and methods
A literature search for studies investigating different 
forms of BMS management was performed in PubMed, 
European Union Drug Regulating Authorities Clinical 
Trials Database (EudraCT), ClinicalTrials.gov, and Co-
chrane Central Register of Controlled Trials (CENTRAL), 
using the Population/Interest/Context (PICO) framework 
and the following search terms: “burning mouth syn-
drome”, “BMS”, “alpha-lipoic acid” AND “burning mouth 
syndrome”, and “clonazepam” AND “burning mouth syn-
drome”.30 No restrictions on the study size, year or duration 
were set. Titles were screened for relevance and duplicates 
were removed, while abstracts were screened according 
to the Preferred Reporting Items for Systematic Reviews 
and Meta-Analyses (PRISMA) recommendations.31 Trials 
that investigated the efficacy of different management ap-
proaches for BMS were included (Tables 1,2). The study 
populations included adult patients undergoing pharma-
cological or non-pharmacological treatment compared to 
placebos/controls for BMS management, with random-
ized controlled trials (RCTs) and case studies screened 
for relevancy.
Outcome measures 
The primary efficacy outcome was the improvement in 
the VAS and Oral Health Impact Profile (OHIP) scores. 
Pharmacological management included alpha-lipoid acid 
(ALA), clonazepam, capsaicin, amisulpride, fluoxetine, 
trazodone, milnacipran, St. John’s wort (Hypericum per-
foratum extract), melatonin, bupivacaine, benzydamine, 
and lidocaine lingual nerve injection (Table 1).
Results
Pharmacological management of burning 
mouth syndrome 
As BMS appears to be associated with psychiatric co-
morbidities, a number of psychotropic drugs are used in 
its management, including antidepressants and clona-
zepam (Table  1)2; psychotherapy has also been used 
(Table 2).
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Alpha-lipoic acid
Alpha-lipoic acid is a free-radical scavenger, and its me-
tabolite – dihydrolipoic acid – has antioxidant properties 
and can regenerate endogenous antioxidants (vitamin E, 
vitamin C and glutathione).32 Alpha-lipoic acid is con-
sidered an  effective medication for BMS management, 
as highlighted by the evidence obtained from trials mea-
suring its efficacy by means of various methods,33–44 with 
some heterogeneity among the studies (Table 1). An  in-
teresting comparison with low-level laser therapy (LLLT) 
showed that both LLLT and ALA were efficient in treating 
BMS.45
Benzodiazepines 
Benzodiazepines are hypnotics/sedatives that potenti-
ate the action of the inhibitory neurotransmitter gamma 
aminobutyric acid (GABA).46 We found 3 trials that com-
pared the efficacy of clonazepam against a placebo using 
the VAS scores.47–49 The overall results proved the effec-
tiveness of  clonazepam, as highlighted by a  significant 
reduction in the VAS scores. Systemic clonazepam pre-
sented the best efficacy, with more than 70% of patients 
showing the partial or complete resolution of  their oral 
symptoms as compared to just over 55% of  patients on 
diazepam.50 Topical clonazepam was also effective, and 
considered more cost-effective than amisulpride, paro-
xetine and sertraline,51 while prazepam showed some ef-
ficacy as well.52
Capsaicin 
We found 4 studies that measured the efficacy of cap-
saicin.35,53–55 The overall results showed a positive effect 
and a possible beneficial role of capsaicin in BMS man-
agement.
Antidepressants 
Selective serotonin reuptake inhibitors (SSRIs) have 
low side-effect profiles and are particularly efficient in 
psychogenic BMS management.56 At low doses, they 
inhibit serotonin reuptake, and at high doses, they may 
inhibit noradrenaline reuptake as well.46 There have not 
been many trials pitting SSRIs against a placebo or control 
medication (Table 1), and most of the available evidence 
comes from case studies. Sertraline, a widely used anti-
depressant, resulted in a reduction in the severity of sto-
matodynia.57 Paroxetine proved to be efficacious, with 
complete pain remission in more than 70% of patients.58 
In 1 study, painful burning sensations were elicited with 
fluoxetine treatment, and citalopram used as an alterna-
tive led to the remission of BMS associated with depres-
sion.59 On the other hand, clomipramine reduced pain in 
BMS patients at a level similar to a placebo.60
Venlafaxine and duloxetine are serotonin-norepi-
nephrine reuptake inhibitors (SNRIs). Venlafaxine with 
clonazepam were successful in patients unresponsive to 
anticonvulsants and antidepressants.11 Duloxetine was 
observed to significantly relieve pain in case reports, and 
led to symptom remission and improvement in the qua-
lity of life (QoL).61,62 Moclobemide is a reversible inhibitor 
of monoamine oxidase, and it reduced anxiety, depression 
and the VAS scores among BMS patients.63
Milnacipran blocks serotonin and norepinephrine 
reuptake. It has a simple pharmacokinetics profile and no 
inhibitory effects on cytochrome P450 enzymes, so it is 
recommended for patients with multiple treatment regi-
mens.64 Low-dose milnacipran (30 mg daily) had a poor 
response; the cumulative improvement rate increased to 
68% when the daily dose was increased from 60  mg to 
90  mg.65 Milnacipran reportedly brought about signifi-
cant reductions in the VAS scores,66 reduced depression 
and improved patients’ QoL,67 but there have not been 
enough trials comparing milnacipran to a placebo or con-
trol medication (Table 1). Most of the available evidence 
of  the efficacy of  milnacipran comes from case studies, 
such as that of a 71-year-old with no satisfactory response 
to psychotropic drugs who recovered from BMS when 
sertraline was replaced with milnacipran.68
Antipsychotics and anti-Parkinson medications 
For antipsychotics and anti-Parkinson drugs, there is 
not enough data comparing a  placebo or control medi-
cation with these medications, and most of the evidence 
comes from case studies. Olanzapine, an  antipsychotic, 
caused rapid significant improvement in treating BMS,69 
even in patients unresponsive to milnacipran or paro-
xetine.70 Aripiprazole ameliorated chronic burning pain,71 
while levosulpiride and amisulpride alleviated oral symp-
toms.72,73 A case of refractory BMS showed complete re-
lief after treatment with pramipexol.74 The BMS symp-
toms also responded to levodopa.7
Anticonvulsants 
Pregabalin was successful in patients unresponsive to 
milnacipran or duloxetine.75 Gabapentin − a  structural 
analog of GABA − reduced oral burning, while nortrip-
tyline and sertraline were contraindicated.76 However, 
another study failed to confirm the efficacy of gabapentin 
in BMS.77
Non-pharmacological management  
of burning mouth syndrome 
The most common non-pharmacological interventions 
are LLLT, psychotherapy and acupuncture.
We found 4 trials measuring the efficacy of LLLT using 
the VAS scores78–81 and 3 trials measuring its efficacy 
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using OHIP (Table  2).79,81,82 The overall results showed 
positive effects on both VAS and OHIP. Interestingly, 
a comparison with ALA showed similar efficacy.45
Two trials measured the efficacy of  psychotherapy in 
alleviating the BMS symptoms,40,83 but there have not 
been enough trials studying the efficacy of acupuncture 
as compared to a placebo or control medication (Table 2).
Discussion
Both the diagnosis and management of  BMS are un-
clear.3 Burning mouth syndrome is known as a  chronic 
condition with pain intensity increasing from morning 
to evening.84 The tongue is the most commonly affected 
site, followed by the lower lip and the hard palate.84 Burn-
ing mouth syndrome could be due to immunological or 
endocrine etiology, and some recent evidence suggests 
neurophysiological mechanisms, such as a  peripheral 
small-fiber neuropathy or central neuropathic distur-
bances.9 Risk factors include metabolic disorders, vitamin 
deficiencies85 or medications, i.a., angiotensin-converting 
enzyme inhibitors and anticoagulants.86
The prevalence of BMS can be especially high in psy-
chiatric patients,87 and it is associated with comorbidities 
such as depression and anxiety.88 Assessment and out-
come measurements include the VAS scores, QoL ratings, 
taste, and the salivary flow.2
Multiple kinds of pharmacological treatment have been 
tried, including ALA, milnacipran, benzodiazepines, an-
tidepressants, anticonvulsants, and atypical antipsycho-
tics (Table 3).87 Topical clonazepam is used for peripheral 
BMS, while central BMS is managed with antidepressants, 
anti-seizure medications or antipsychotics,89 but the evi-
dence of their efficacy is weak, as the power of the studies 
and the numbers of patients have been relatively low, and 
most studies have had short follow-up periods with high 
variability.
Burning mouth syndrome could have a  neuropathic 
origin, and experts recommend neuropathic pain agents, 
such as amitriptyline, gabapentin, benzodiazepines, anti-
psychotics,90 or mood-altering interventions.91 Our study 
highlights that ALA, clonazepam and capsaicin may bring 
promising results (Table  4); however, more studies are 
needed, with longer follow-up periods and larger num-
bers of patients. Alpha-lipoic acid and clonazepam have 
shown modest evidence of decreasing BMS.92 The overall 
quality of the evidence of effectiveness remains low for all 
pharmacological and non-pharmacological interventions.
Our review has some limitations. There was high hete-
rogeneity among the studies and there were few clini-
cal trials for most of the management options. Different 
methods were used to present the findings, while some 
trials had missing data (Tables 1,2).
Combination treatment has shown promising results. 
Alpha-lipoic acid with gabapentin,41 sertraline with cognitive 
behavioral therapy,93 and tranylcypromine with low-dose 
anxiolytics and psychotherapy have been effective in refrac-
tory BMS.94 Non-pharmacological interventions, such as 
LLLT or psychotherapy, have shown some efficacy. However, 
large-scale clinical trials with long follow-up periods are still 
needed to confirm these findings.89 Treatment should be tai-
lored with careful history-taking and consultations among 
a variety of health professionals, including psychiatrists, den-
tists, pain specialists, and neurologists with a  special inte-
rest in headaches, to avoid potential delays in diagnosis.85,95 
A clinical diagnosis should include the assessment of the nu-
tritional status and comprehensive dental evaluation.96 The 
management of BMS should include managing anxiety, de-
pression and pain disorders, ruling out treatable conditions, 
Table 3. Summary of the available evidence for the pharmacological 
management of burning mouth syndrome (BMS)
Medication As per current clinical research
Alpha-lipoic acid
Positive outcome demonstrated with improvement 
in the VAS scores in several trials; however, RCT 
failed to support its role – further research needed.
Milnacipran
Weak scientific evidence that milnacipran (60–90 mg) 
could result in a significant reduction in the VAS scores.
Benzodiazepines
Research suggests the efficacy of systemic 
clonazepam or its application in the form of oral 
rinse – large clinical trials still needed to confirm.
Antidepressants
Scientific evidence mostly from case studies. Sertraline 
and paroxetine were efficacious with a reduction in 
the severity of BMS. In case reports, venlafaxine and 
duloxetine significantly relieved pain. Moclobemide 




In case studies, olanzapine and aripiprazole caused 
improvement – RCTs lacking. Weak scientific evidence 
for the efficacy of amisulpride. Case studies highlighted 
pramipexol and levodopa as promising medications.
Anticonvulsants
Case studies highlighted gabapentin and 
pregabalin as promising medications despite the 
presence of some contradictory results. One clinical 
trial highlighted the possible efficacy of gabapentin, 
especially in combination with ALA.
RCT – randomized clinical trial.
Table 4. Characteristics of the main pharmacological therapies for the 
management of burning mouth syndrome (BMS)




in 2–3 divided 
doses
2–4 weeks
rare minor abdominal 





2–4 weeks fatigue, muscle weakness, 
nausea, somnolence, rash, 









mild abdominal pain, and 
rarely hypersensitivityoral rinse  
0.025% TID
2–4 weeks
Milnacipran 30–90 mg/day 2–4 weeks
dizziness, hot flash, nausea, 
insomnia, palpitations, rash, 
headache, and xerostomia
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and discussing different management options with the pa-
tient.97 Non-pharmacological interventions could be tried 
first, if clinically appropriate, and compatible with the pa-
tient’s preferences and the severity of the symptoms. If phar-
macotherapy is appropriate, ALA or capsaicin could be first 
choice because of favorable side-effect profiles, while clona-
zepam or milnacipran could be second-line medications for 
BMS management due to their side effects − particularly 
cognitive ones − and an increased risk of dependence associ-
ated with benzodiazepines.
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